Glycoprotein as a Target for SARS-CoV-2 Antibody Development

Currently, the application of neutralizing antibody against certain targets has emerged as one of the most effective ways to boost immune responses against infectious agents or to fight malignant tumors. As a first-class antibody development company around the world, Creative Biolabs is specialized in novel neutralizing antibody development for 2019 Novel Coronavirus (SARS-CoV-2).

Introdiction of SARS-CoV-2

SARS-CoV-2, also known as Wuhan coronavirus, is a new contagious virus first found in Wuhan, China. It’s a positive-sense, single-stranded RNA coronavirus and causes the ongoing 2019–20 Wuhan coronavirus outbreak. Coronaviruses are a family of large, enveloped RNA viruses of both medical and veterinary importance, which cause potentially deadly diseases in mammals and birds. Typically, they can cause several symptoms in different animals, some strains cause diarrhea in turkeys and pigs, while most infections are some alike to bad cold, leading to mild to moderate upper respiratory problems (e.g., a runny nose and sore throat). Generally, coronaviruses spread via airborne droplets of fluid produced by infected individuals in humans. Some of the strains can cause death in humans, for example, Middle East respiratory syndrome (MERS), severe acute respiratory syndrome (SARS), and SARS-CoV-2.

Fig.1 Glycoproteins of coronavirus.

Antibody Development Against Glycoprotein

There are five structural proteins in the coronavirus genomes: Spike (S), Membrane (M), Envelope (E) glycoproteins, Hemagglutinin Esterase (HE) and Nucleocapsid (N) protein. Among these proteins, N protein and envelope proteins are expressed in all virions, however HE is just present in some beta coronaviruses. Besides, it is considered that interaction between these proteins are very important for huddling together of virus particles.

mAb114, a monoclonal antibody targeting the Ebola virus glycoprotein, binds to an extremely conserved region of amino acids in the receptor binding domain of EBOV variants. mAb114 is able to block the interaction of the glycoprotein with the NPC1 receptor, therefor preventing virus entry into the cytoplasm of the host cell. Furthermore, mAb114 binds to the receptor-binding domain, thus reducing the risk of escape mutants (mutants capable of evading the original host immune response). In addition, an open-label phase 1 study showed that mAb114 was well tolerated, showed linear pharmacokinetics, and was easily and rapidly infused, making it an attractive and deployable option for treatment in outbreak settings (Gaudinski, 2019). In summary, glycoprotein maybe a potential target for SARS-CoV-2 antibody discovery, and Creative Biolabs is dedicated to helping our clients in the antibody discovery process of SARS-CoV-2.

Antibody Development Services at Creative Biolabs

With years of experience in the antibody development field, Creative Biolabs has built a variety of antibody development platforms. Our scientists are ready to make your project succeed.

• Phage Display & Antibody Library Services
• Single Domain Antibody (sdAb) Services
• Custom Antibody & Hybridoma Services
• Native™ Antibody Discovery Services
• In Vitro Display & Other Services

Creative Biolabs will continue to advance technologies to ensure the success for customers worldwide. Please directly contact us with your project request for more details.

Reference

1. Gaudinski, M. R., et al. Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study. The Lancet. 2019, 393, 889-898.

For Research Use Only. We do not provide direct services or products for patients.